Effects of levofloxacin and doxycycline on interleukin-6 production of Chlamydia trachomatis-infected human synovial fibroblasts

Chemotherapy

Volumn 53, Issue 5, 2007, Pages 332-337

  Ikeda Dantsuji, Yurika ^a   Konomi, Ichiro ^a   Nagayama, Ariaki ^a  

^a FUKUOKA UNIVERSITY   (Japan)

Author keywords

Chlamydia trachomatis; Doxycycline; Interleukin 6; Levofloxacin; Reactive arthritis

Indexed keywords

DOXYCYCLINE; INTERLEUKIN 6; LEVOFLOXACIN;

ARTICLE; BACTERIAL INFECTION; CELL CULTURE; CHLAMYDIA TRACHOMATIS; DRUG EFFECT; FIBROBLAST; HELA CELL; HUMAN; HUMAN CELL; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; SYNOVIOCYTE;

CELL LINE; CHLAMYDIA TRACHOMATIS; DOXYCYCLINE; FIBROBLASTS; HUMANS; INTERLEUKIN-6; MICROBIAL VIABILITY; OFLOXACIN; SYNOVIAL FLUID;

EID: 34548700805     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000107457     Document Type: Article

References (27)

1. Cates W Jr, Wasserheit JN: Genital chlamydial infections: epidemiology and reproductive sequelae. Am J Obstet Gynecol 1991;164:1771-1781.
2. Rahaman MU, Cheema MA, Schumacher HR Jr, Hudson AP: Molecular evidence for the presence of Chlamydia in the synovium of patients with Reiter's syndrome. Arthritis Rheum 1992;35:521-529.
3. Gaston JS: Reactive arthritis. Rheumatol Eur 1995;24:5-22.
4. Hanada H, Ikeda-Dantsuji Y, Naito M, Nagayama A: Infection of human fibroblast-like cells with Chlamydia trachomatis results in persistent infection and interleukin-6 production. Microb Pathog 2003;34:57-63.
5. Valtonen VV, Leirisalo M, Pentikainen PJ, Rasanen T, Seppala I, Larinkari U, Ranki M, Koskimies S, Malkamaki M, Makela PH: Triggering infections in reactive arthritis. Ann Rheum Dis 1985;44:399-405.
6. Rosenbaum JT, Cugnini R, Tara DC, Hefeneider S, Ansel JC: Production and modulation of interleukin 6 synthesis by synoviocytes derived from patients with arthritic disease. Ann Rheum Dis 1992;51:198-202.
7. Rodel J, Straube E, Lungershausen W, Hartmann M, Groh A: Secretion of cytokines by human synoviocytes during in vitro infection with Chlamydia trachomatis. J Rheumatol 1998;25:2161-2168.
8. Mielants H, Veys EM: The guts and reactive arthritis. Rheumatol Eur 1995;24:9-11.
9. Toivanen A, Mottonen T: Ankylosing spondylitis: current approaches to treatment. BioDrugs 1998;10:193-200.
10. Toivanen A: Bacteria-triggered reactive arthritis. Drugs 2001;61:343-351.
11. Laasila K, Laasonen L, Leirisalo-Repo M: Antibiotics treatment and long term prognosis of reactive arthritis. Ann Rheum Dis 2003;62:655-658.
12. Yli-Kerttula T, Luukkainen R, Yli-Kerttula U, Mottonen T, Hakola M, Sanila M, Parviainen J, Uksila J, Vainionpaa R, Toivanen A: Effect of a three month course of ciprofloxacin on the outcome of reactive arthritis. Ann Rheum Dis 2000;59:565-570.
13. Rodel J, Straube E, Lungershausen W, Hartmann M, Groh A: Primary cultivation of human synovial cells from nonrheumatic synovial tissue and fluid. Exp Toxic Pathol 1996;48:243-247.
14. Nagayama A, Nakao T, Taen H: In vitro activities of ofloxacin and four other new quinoline-carboxylic acids against Chlamydia trachomatis. Antimicrob Agents Chemother 1988;32:1735-1737.
15. Notomi T, Ikeda Y, Nagayama A: Minimum inhibitory and minimal lethal concentration against Chlamydia trachomatis dependent on the time of addition and duration of the presence of antibiotics. Chemotherapy 1999;45:242-248.
16. Takahashi S, Hagiwara T, Shiga S, Hirose T, Tsukamoto T: In vitro analysis of the change in resistance of Chlamydia trachomatis under exposure to sub-MIC levofloxacin for therapeutic term. Chemotherapy 2000;46:402-407.
17. Leirisalo-Repo M: Are antibiotics of any use in reactive arthritis? APMIS 1993;101:575-581.
18. Lauhio A, Leirisalo-Repo M, Lahdevirta J, Saikku P, Repo H: Double-blind, placebo-controlled study of three-month treatment with lymecycline in reactive arthritis with special reference to Chlamydia trachomatis. Arthritis Rheum 1991;34:6-14.
19. Bardin T, Euel C, Cornelis T: Antibiotic treatment of venereal disease and Reiter's syndrome in a Greenland population. Arthritis Rheum 1992;35:190-194.
20. Smieja M, MacPherson DW, Kean W, Schmuck ML, Goldsmith CH, Buchanan W, Hart LE, Mahony JB: Randomised, blind, placebo controlled trial of doxycycline for chronic seronegative arthritis. Ann Rheum Dis 2001;60:1088-1094.
21. Sieper J, Fendler C, Laitko S, Sorensen H, Gripenberg-Lerche C, Hiepe F, Alten R, Keitel W, Groh A, Uksila J, Eggens U, Granfors K, Braun J: No benefit of long-term ciprofloxacin treatment in patients with reactive arthritis and undifferentiated oligoarthritis. Arthritis Rheum 1999;42:1386-1396.
22. Fryden A, Bengtsson A, Foberg U, Svenungsson B, Castor B, Karnell A, Schvatcz R, Lindblom B, Kihlstrom E: Early antibiotic treatment of reactive arthritis associated with enteric infections: clinical and serological study. BMJ 1990;301:1299-1302.
23. Locht H, Kihlstrom E, Lindstrom FD: Reactive arthritis after Salmonella among medical doctors: study of an outbreak. J Rheumatol 1993;20:845-848.
24. Reveneau N, Crane DD, Fisher E, Caldwell HD: Bactericidal activity of first-choice antibiotics against gamma interferon-induced persistent infection of human epithelial cells by Chlamydia trachomatis. Antimicrob Agents Chemother 2005;49:1787-1793.
25. Brandt KD, Mazzuca SA, Katz BP, Lane KA, Buckwalter KA, Yocum DE, Wolfe F, Schnitzer TJ, Moreland LW, Manzi S, Bradley JD, Sharma L, Oddis CV, Hugenberg ST, Heck LW: Effects of doxycycline on progression of osteoarthritis. Arthritis Rheum 2005;52:2015-2025.
26. Keat A, Thomas B, Dixey J, Osborn M, Sonnex C, Taylor-Robinson D: Chlamydia trachomatis and reactive arthritis: the missing link. Lancet 1987;1:72-74.
27. Nanagara R, Li F, Beutler A, Hudson A, Schmacher HR Jr: Alteration of Chlamydia trachomatis biologic behavior in synovial membranes: suppression of surface antigen production in reactive arthritis and Reiter's syndrome. Arthritis Rheum 1995;38:1410-1417.